Found vs Henry Meds vs TrimRx (2026)
On tirzepatide, the order is Found ($289) → Henry Meds↗ ($349) → TrimRx↗ ($349) — gaps of $60 and then $0 a month, a $720 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The three records, one screen
Found: the record, condensed
Start with the load-bearing figure: $289 a month, all-in, is what Found charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.
To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.
Start with the load-bearing figure: $289 a month, all-in, is what Found charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.
Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.
Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗
Henry Meds: the record, condensed
Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes Henry Meds unusually easy to compare and unusually easy to leave.
To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.
On semaglutide, the number that matters at Henry Meds is $179 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.
Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.
Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗
TrimRx: the record, condensed
Start with the load-bearing figure: $349 a month, all-in, is what TrimRx charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes TrimRx unusually easy to compare and unusually easy to leave.
To place the number: #11 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.
Start with the load-bearing figure: $299 a month, all-in, is what TrimRx charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes TrimRx unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #17 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.
Operationally at TrimRx: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the TrimRx page · visit TrimRx ↗
Prices, gaps, and what sits inside them
Found holds the low ground at $289 — dose-flat, so that figure is a ceiling with no membership attached. Henry Meds follows at $349 (+$60/mo, $720/yr). TrimRx tops the trio at $349 (+$60/mo over the leader, $720/yr) — note its record’s watch-out below.
The semaglutide picture reshuffles the order: Henry Meds $179 → Found $289 → TrimRx $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.
Who wins what
Cheapest month-to-month: Found ($289); cheapest 12-month path: Found ($3,468); cheapest semaglutide of the three: Henry Meds ($179).
Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Found vs Henry Meds · Found vs TrimRx · Henry Meds vs TrimRx.
Everything besides the three prices
Memberships: Found none; Henry Meds none; TrimRx none. Structures: Found dose-flat; Henry Meds dose-flat; TrimRx dose-flat. Pharmacies: Found not named; Henry Meds not named; TrimRx not named. States: Found — most states; Henry Meds — most states; TrimRx — not published. Exit terms: Found — membership recurs; prepaid terms are paid up front; Henry Meds — check terms before prepaying; TrimRx — check terms before prepaying.
The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Found third-party reported (2026-08-05); Henry Meds third-party reported (2026-08-05); TrimRx source-verified (2026-08-05).
The trio on semaglutide, across time
3 mo: Henry Meds $537 vs Found $867 vs TrimRx $897 6 mo: Henry Meds $1,074 vs Found $1,734 vs TrimRx $1,794 12 mo: Henry Meds $2,148 vs Found $3,468 vs TrimRx $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.
The trio, annualized
Found: $3,468/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed; TrimRx: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $1,440 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.
The elimination read
A three-way choice is really two eliminations, so run them in order. Eliminate TrimRx first unless it names its edge: at $349 it carries a $60/month premium over the floor of this trio — $720 a year, about 2.5 extra months of therapy at Found’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Henry Meds’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $60/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is Found at $289, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.
The same trio on best published rate: Found $289 → Henry Meds $349 → TrimRx $349 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Found $867, Henry Meds $1,047, TrimRx $1,047; 6 months — Found $1,734, Henry Meds $2,094, TrimRx $2,094. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.
The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): Found 3/5, Henry Meds 3/5, TrimRx 4/5. TrimRx discloses the most and Found the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.
Read as a decision: start from Found and make the other two argue upward. Henry Meds’s case is its structure; TrimRx’s case must be worth $720 a year in named features — the honest unit being months of medication (2.5 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.
Frequently asked
Which is cheapest: Found, Henry Meds, or TrimRx?
Found, at $289/month all-in tirzepatide — $60 under Henry Meds and $60 under TrimRx; on semaglutide the cheapest of the three is Henry Meds at $179. Captured 2026-08-09.
Which of the three is best over a full year?
Found’s best path prices twelve months at $3,468; monthly-billed years run Found $3,468, Henry Meds $4,188, TrimRx $4,188.
Are these rankings paid or editorial?
Neither — they are sorts of the public dataset on the all-in maintenance basis, regenerated on every data change; the methodology page defines the basis and the JSON lets you recompute every figure here.